WallStSmart

Advanced Micro Devices Inc (AMD)vsAmgen Inc (AMGN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Advanced Micro Devices Inc generates 1% more annual revenue ($37.45B vs $37.22B). AMGN leads profitability with a 21.0% profit margin vs 13.4%. AMD appears more attractively valued with a PEG of 1.05. AMGN earns a higher WallStSmart Score of 62/100 (C+).

AMD

Buy

61

out of 100

Grade: C+

Growth: 9.3Profit: 6.0Value: 4.3Quality: 9.0
Piotroski: 6/9Altman Z: 3.74

AMGN

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 9.0Value: 4.7Quality: 5.0
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AMD.

AMGNFair Value (-2.2%)

Margin of Safety

-2.2%

Fair Value

$321.89

Current Price

$331.70

$9.81 premium

UndervaluedFair: $321.89Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMD6 strengths · Avg: 9.7/10
Market CapQuality
$666.04B10/10

Mega-cap, among the largest globally

Revenue GrowthGrowth
37.8%10/10

Revenue surging 37.8% year-over-year

EPS GrowthGrowth
91.2%10/10

Earnings expanding 91.2% YoY

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.7410/10

Safe zone — low bankruptcy risk

Free Cash FlowQuality
$2.57B8/10

Generating 2.6B in free cash flow

AMGN5 strengths · Avg: 9.2/10
Return on EquityProfitability
101.3%10/10

Every $100 of equity generates 101 in profit

Operating MarginProfitability
33.8%10/10

Strong operational efficiency at 33.8%

Market CapQuality
$177.71B9/10

Large-cap with strong market position

Profit MarginProfitability
21.0%9/10

Keeps 21 of every $100 in revenue as profit

Free Cash FlowQuality
$1.48B8/10

Generating 1.5B in free cash flow

Areas to Watch

AMD2 concerns · Avg: 3.0/10
Price/BookValuation
11.8x4/10

Trading at 11.8x book value

P/E RatioValuation
137.1x2/10

Premium valuation, high expectations priced in

AMGN3 concerns · Avg: 4.0/10
PEG RatioValuation
2.184/10

Expensive relative to growth rate

Price/BookValuation
19.5x4/10

Trading at 19.5x book value

EPS GrowthGrowth
4.4%4/10

4.4% earnings growth

Comparative Analysis Report

WallStSmart Research

Bull Case : AMD

The strongest argument for AMD centers on Market Cap, Revenue Growth, EPS Growth. Revenue growth of 37.8% demonstrates continued momentum. PEG of 1.05 suggests the stock is reasonably priced for its growth.

Bull Case : AMGN

The strongest argument for AMGN centers on Return on Equity, Operating Margin, Market Cap. Profitability is solid with margins at 21.0% and operating margin at 33.8%.

Bear Case : AMD

The primary concerns for AMD are Price/Book, P/E Ratio. A P/E of 137.1x leaves little room for execution misses.

Bear Case : AMGN

The primary concerns for AMGN are PEG Ratio, Price/Book, EPS Growth.

Key Dynamics to Monitor

AMD profiles as a growth stock while AMGN is a mature play — different risk/reward profiles.

AMD carries more volatility with a beta of 2.40 — expect wider price swings.

AMD is growing revenue faster at 37.8% — sustainability is the question.

AMD generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

AMGN scores higher overall (62/100 vs 61/100), backed by strong 21.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Advanced Micro Devices Inc

TECHNOLOGY · SEMICONDUCTORS · USA

Advanced Micro Devices, Inc. (AMD) is an American multinational semiconductor company based in Santa Clara, California, that develops computer processors and related technologies for business and consumer markets. AMD's main products include microprocessors, motherboard chipsets, embedded processors and graphics processors for servers, workstations, personal computers and embedded system applications.

Visit Website →

Amgen Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.

Visit Website →

Want to dig deeper into these stocks?